The combination of accelerating EBITDA, strong cash flow, and clear path to >$250M annualized revenue by end of 2026 suggests meaningful operating leverage. Traders should monitor Q1 2026 EBITDA trajectory, as management expects profitability to return in Q2 following front-loaded patient acquisition spend.
Price Chart
Executive Summary
LifeMD reported strong full-year 2025 results with 25% revenue growth to $194.1 million and a 309% increase in adjusted EBITDA to $15.3 million. Q4 revenue rose 4% to $46.9 million with adjusted EBITDA surging 348% year-over-year. The company exited 2025 with $36.8 million in cash and no debt, and provided 2026 guidance projecting annualized run-rate revenue and adjusted EBITDA exceeding $250 million and $25 million, respectively, by Q4 2026.
Key Financial Metrics
Key Facts
- Full-year 2025 revenue grew 25% to $194.1 million
- Adjusted EBITDA increased 309% to $15.3 million for the year
- Q4 revenue up 4% to $46.9 million; adjusted EBITDA up 348% to $4.8 million
- Exited 2025 with $36.8 million in cash and zero debt
- Launched oral Wegovy post-year-end; Q1 patient sign-ups at record levels
- 2026 guidance: $220M–$230M revenue, $12M–$17M adjusted EBITDA, with run-rate targets of >$250M revenue and >$25M adjusted EBITDA by Q4 2026
Financial Impact
Revenue growth of 25% and EBITDA tripling in 2025, with strong cash position enabling aggressive growth investments. 2026 run-rate targets imply ~28% revenue and ~65% EBITDA growth over 2025 actuals.
Risk Factors
- Adjusted EBITDA guidance for Q1 2026 shows a $4M–$5M loss due to heavy investment, indicating near-term margin pressure
- Ongoing litigation costs included in adjusted EBITDA reconciliation, which may persist
- Execution risk in scaling women’s health and oral Wegovy adoption despite strong early signals
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3252294 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 7, 2026 19d ago | SC 13G/A | $2.79 | awaiting T+20 | — | $2.08 (−25.45%) |
Sep 22, 2026 4w ago | Press Release | $3.05 $2.14 | ▼ −29.84% | ▼ −30.52% | $2.08 (−31.80%) |
Aug 5, 2026 11w ago | Press Release | $3.40 $3.05 | ▲ +10.29% | ▲ +10.89% | $2.08 (+38.82%) |
Apr 27, 2026 26w ago | Press Release | $4.57 $4.24 | ▼ −7.22% | ▼ −12.18% | $2.08 (−54.49%) |
Mar 31, 2026 29w ago | Press Release | $3.61 $4.43 | ▲ +22.71% | ▲ +13.29% | $2.08 (−42.38%) |
Mar 24, 2026 30w ago | Press Release | $3.90 $4.54 | ▲ +16.41% | ▲ +8.55% | $2.08 (−46.67%) |
Mar 9, 2026 33w ago | Press Release | $3.91 $3.47 | ▼ −11.25% | ▼ −11.10% | $2.08 (−46.80%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers